Drug Trial Radar · NCT04733118
Chemotherapy-Free pCR-Guided Strategy With Trastuzumab-pertuzumab and T-DM1 in HER2-positive Early Breast Cancer
Last checked: Nov 20, 2026Latest source record: Apr 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
393
Actual
Start
Aug 5, 2021
Primary completion
Mar 2027
Study completion Mar 2028
Sponsor
- Lead sponsor
- MedSIRAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Hoffmann-La Roche
- First posted
- Feb 1, 2021
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multicenter, open-label, single-arm, one-stage, phase II study to assess the efficacy of a chemotherapy-free pathological complete response (pCR)-guided strategy with trastuzumab and pertuzumab (given as a subcutaneous fixed-dose combination) and T-DM1, for patients with previously untreated HER2-positive early breast cancer.
Conditions
- Early Breast Cancer
Interventions
Trastuzumab and Pertuzumab (FDC SC) and T-DM1Drug
Patients will receive Trastuzumab and Pertuzumab as a subcutaneous fixed-dose combination (PH FDC SC) (± ET depending on HR status) for 8 3-week cycles, on day 1 only. ET will consist of letrozole for post-menopausal women or tamoxifen ± ovarian function suppression (OFS) for pre-menopausal women administered continuously. Men will receive tamoxifen. After completing neoadjuvant therapy, a final breast MRI will be performed 2 weeks prior to surgery. Surgery will be performed within 4 weeks after completion of the last cycle of PH FDC SC. Adjuvant systemic therapy will start within 4 weeks from surgery. There will be three different cohorts depending on pathological report: * Cohort A: PH FDC SC ± ET for 10 additional 3-week cycles * Cohort B: T-DM1 ± ET for 10 cycles * Cohort C: T-DM1 ± ET for 10 cycles, with possibility of physician's choice chemotherapy before adjuvant T-DM1.
Primary outcomes
What the sponsor says the trial is designed to measure.
- 3-year recurrence-free interval (3y-RFI)Time frame: 3 years
- Global health status declineTime frame: 1 year
Locations
41 sites in 5 countries. Site status is shown where the registry gives one.
UMHAT Sveti Ivan Rilski EAD Department of Medical Oncology
Sofia, Bulgaria
Praxisnetzwerk Hämatologie und intern. Onkologie
Cologne, Germany
Evangelisches Krankenhaus Bethesda
Duisburg, Germany
Kliniken Essen Mitte
Essen, Germany
Universitätsklinikum Essen Frauenklinik
Essen, Germany
Universitätsklinikum Mannheim GmbH
Manheim, Germany
Klinikum Ernst von Bergmann
Potsdam, Germany
Békés county hospital
Békés, Hungary
Tolna County Balassa János Hospital
Szekszárd, Hungary
Azienda Ospedaliero Universitaria Di Bologna - Policlinico S.Orsola-Malpighi
Bologna, Italy
AO Ospedale Civile Legnano
Milan, Italy
Istituto Europeo di Oncologia - NC
Milan, Italy
Ospedale San Gerardo
Monza, Italy
Azienda Ospedaliero-Universitaria di Parma
Parma, Italy
Ospedale Guglielmo da Saliceto
Piacenza, Italy
Fondazione Policlinico Universitario Agostino Gemelli
Roma, Italy
Centro Oncológico de Galicia
A Coruña, Spain
Hospital Universitario A Coruña
A Coruña, Spain
Hospital General Universitario de Alicante
Alicante, Spain
Institut Català d' Oncologia Badalona (ICO)
Badalona, Spain
Hospital Universitari Dexeus - Grupo Quirónsalud
Barcelona, Spain
VHIO Vall d'Hebron Institute of Oncology
Barcelona, Spain
Hospital Universitario de Basurto
Bilbao, Spain
Consorcio Hospitalario Provincial De Castelló
Castellon, Spain
Hospital Universitario Clínico San Cecilio de Granada
Granada, Spain
Complejo Hospitalario de Jaen
Jaén, Spain
Complejo Asistencial Universitario de León
León, Spain
Hospital Universitari Arnau de Vilanova de Lleida
Lleida, Spain
Hospital Clínico San Carlos
Madrid, Spain
Hospital Quirón San Camilo- Ruber Juan Bravo
Madrid, Spain
Hospital Ramón y Cajal
Madrid, Spain
Hospital Universitario Virgen del Rocio
Seville, Spain
Hospital Universitario de Torrejón
Torrejón, Spain
Instituto Valenciano de Oncología (IVO)
Valencia, Spain
Hospital La Fe
Valencia, Spain
Consorcio Hospital General de Valencia
Valencia, Spain
Hospital Arnau de Vilanova de Valencia
Valencia, Spain
Hospital Clinico Universitario de Valencia
Valencia, Spain
ICO L'Hospitalet - Instituto Catalán de Oncología
L'Hospitalet de Llobregat, Barcelona, Spain
Hospital Universitario Reina Sofia
Córdoba, Cordoba, Spain
Showing 40 of 41 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.